Pharmicell Co.,Ltd.
Financials
Valuation Metrics
Pharmicell Co.,Ltd.'s Market Cap is ₩7531B. At end of 2025 it was ₩8719B. Ranked #357 of 2,421 in KR market (top 15%), #246 of 781 on KOSPI (top 31%), #40 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 17%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 753.05B KRW | KR#357/2,421 Sec#40/231 |
| Revenue | 135.94B KRW | KR#1,239/2,421 Sec#76/231 |
| Net Income | 46.53B KRW | KR#441/2,421 Sec#26/231 |
| Total Assets | 184.15B KRW | KR#1,371/2,421 Sec#102/231 |
| Net Assets | 143.37B KRW | KR#1,170/2,421 Sec#85/231 |
| Employees | 146 | KR#1,348/2,421 Sec#109/231 |
| Value | ||
| P/E | 16.18x | KR#1,081/2,421 Sec#64/231 |
| P/B | 5.25x | KR#2,256/2,421 Sec#194/231 |
| PEG | 0.13x | KR#464/2,421 Sec#25/231 |
| P/S | 5.54x | KR#2,168/2,421 Sec#142/231 |
| EV/EBITDA | 17.32x | KR#940/2,421 Sec#54/231 |
| FCF Yield | 4.46% | KR#884/2,421 Sec#50/231 |
| Profitability | ||
| ROE | 32.46% | KR#47/2,421 Sec#5/231 |
| ROA | 25.27% | KR#27/2,421 Sec#5/231 |
| Op. Margin | 32.42% | KR#45/2,421 Sec#10/231 |
| Revenue Growth | 51.28% | KR#200/2,421 Sec#26/231 |
| Earnings Growth | 124.70% | KR#348/2,421 Sec#22/231 |
| Financial Health | ||
| Debt Ratio | 28.45% | KR#551/2,421 Sec#61/231 |
| Total Debt | 25.02B KRW | KR#1,304/2,421 Sec#103/231 |
| FCF | 33.60B KRW | KR#388/2,421 Sec#22/231 |
| Cash | 15.04B KRW | KR#1,425/2,421 Sec#111/231 |
| Current Ratio | 7.15x | KR#167/2,421 Sec#37/231 |
| Net Debt/EBITDA | 0.23x | KR#636/2,421 Sec#37/231 |
| Dividend | ||
| Div. Yield | 0.40% | KR#1,290/2,421 Sec#78/231 |
| Div. Growth | 150.00% | KR#65/2,421 Sec#2/231 |
| Performance | ||
| 1Y Return | 0.32% | KR#725/2,421 Sec#48/231 |
| 1M Return | 10.28% | KR#477/2,421 Sec#32/231 |
| From 52W High | -40.66% | KR#953/2,421 Sec#66/231 |
| 1Y MDD | -56.74% | KR#1,296/2,421 Sec#104/231 |
| Trading | ||
| Volume | 9,911,338 shares | KR#15/2,421 Sec#1/231 |
| Trading Value | 129.58B KRW | KR#21/2,421 Sec#1/231 |
| Foreign Own. | 8.54% | KR#531/2,421 Sec#45/231 |
| Per Share | ||
| EPS | 776 KRW | KR#820/2,421 Sec#60/231 |
| BPS | 2,389 KRW | KR#1,980/2,421 Sec#160/231 |
Company Info
Pharmicell, established in 1968 and renamed in 2011, is a specialized biotech company listed in 1988. It operates a biomedical division, manufacturing and selling the world's first stem cell therapy, and a biochemical division, producing pharmaceutical intermediates and eco-friendly phosphorus flame retardants, in addition to stem cell banking and cosmetics businesses. The company has developed and patented technologies for anticancer immunotherapy dendritic cells and neurological disorder treatments. Pharmicell is actively pursuing innovation through technology development in areas such as mRNA vaccine raw materials and artificial blood, and is headquartered in Gangnam-gu, Seoul.